Amarin Corporation plc — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed February 29, 2024. This is an annual report, not a standalone fourth-quarter report. Amarin is a pharmaceutical company whose business is substantially dependent on VASCEPA (icosapent ethyl), marketed as VAZKEPA in Europe.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue, net | $306.9 million | $369.2 million |
| Net product revenue | $285.3 million | $366.5 million |
| Licensing and royalty revenue | $21.6 million | $2.7 million |
| Gross margin | $165.5 million; 50% of product revenue | $242.5 million; 65% of product revenue |
| Operating loss | $67.6 million | $105.9 million |
| Net loss | $59.1 million; $0.15 per share | $105.8 million; $0.26 per share |
| Cash provided by (used in) operating activities | $6.9 million | $(180.1) million |
- U.S. net product revenue was $273.9 million, down from $359.9 million. U.S. icosapent ethyl market share fell to about 57% from 60%; branded VASCEPA prescriptions declined 8%, while the overall market grew 4%.
- Licensing and royalty revenue rose largely because of milestone revenue and changes in estimates of the remaining performance periods under the Edding and HLS agreements. The company also recorded a $15.1 million adjustment, primarily related to Medicaid rebates, benefiting 2023 product revenue.
- Reported product gross margin fell to 50% from 65%. Excluding restructuring-related inventory charges and inventory write-offs, management reported margins of 66% and 73%, respectively. Restructuring inventory charges were $39.2 million in 2023 versus $18.1 million in 2022.
- Selling, general and administrative expense declined 34% to $199.9 million; research and development expense declined 27% to $22.2 million. These reductions reflect restructuring, lower U.S. promotion and other spending changes.
- Year-end cash and cash equivalents were $199.3 million, short-term investments $121.4 million, and restricted cash $0.5 million. The company reported no debt. Current assets were $725.0 million and current liabilities $259.3 million.
- Total inventory was $336.2 million, including $258.6 million current and $77.6 million long-term inventory; approximately 80% was approved for North America. Net accounts receivable was $133.6 million.
Material changes, outlook and risks
- Restructuring: The July 2023 Organizational Restructuring Program eliminated all U.S. sales-force positions and reduced total headcount by approximately 30%. Amarin expects annual operating-cost savings of about $40 million. Its strategy emphasizes a leaner U.S. model, redesigned European operations and international partnerships.
- Outlook: Amarin suspended net-revenue guidance, citing uncertainty in demand, U.S. generic competition and the European launch. Management said cash and investments were expected to support operations, including the planned repurchase program, for at least 12 months from the financial-statement issuance date; this depends on assumptions and is not a guarantee.
- Share repurchase: In January 2024, the company announced plans to repurchase up to $50 million of ADSs. Implementation requires shareholder and UK High Court approval. The company reported regaining Nasdaq’s minimum-bid-price compliance in January 2024 after an October 2023 deficiency notice.
- Commercial and access risks: U.S. generic competition has pressured price and share. European launches depend on country-specific reimbursement and pricing; Amarin discontinued German operations after failing to agree on reimbursement terms. Commercial success internationally remains dependent on partners, market access and reimbursement.
- Legal and regulatory matters: The filing describes generic-related patent litigation, antitrust lawsuits brought by generic manufacturers and purchaser groups, and ongoing government investigations, including FTC/New York Attorney General inquiries concerning API supply and a DOJ inquiry into historical promotional and copay programs. Amarin says it is cooperating and intends to defend itself; outcomes and potential losses are not clearly estimable in the filing.
- Supply commitments: The company disclosed approximately $37.0 million of future contractual purchase obligations and $186.5 million of contingent obligations tied to supplier regulatory approval or European reimbursement conditions. It recorded an $8.0 million provision for expected reimbursement-related shortfalls; the filing says up to an additional $7.8 million could ultimately be accrued.
- Product and execution risks: The business relies on VASCEPA, third-party manufacturers and a concentrated wholesale customer base. Three customers each represented at least 10% of gross product sales. Safety disclosures include increased reported rates of atrial fibrillation or flutter requiring hospitalization and bleeding in the REDUCE-IT trial.
- Other items: Development of the fixed-dose VASCEPA/statin combination was deprioritized in 2023. The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting as of year-end.
Important facts for investors to verify
- How much of the $40 million expected annual savings is realized, and whether the leaner U.S. commercial model can stabilize branded sales and cash generation.
- U.S. net price, prescription trends, generic share and the timing and size of future gross-to-net adjustments, including Medicaid rebates.
- European reimbursement progress, especially in remaining target markets, and whether partner launches generate material royalties or milestones.
- Inventory usability, sell-through and expiry exposure, supplier minimum-purchase terms, and the final amount of any contingent supply-related charges.
- Developments and potential financial exposure in antitrust litigation, government investigations and other legal proceedings.
- Whether the proposed $50 million repurchase receives required approvals and how it affects liquidity relative to operating needs.